What are the PCSK9 drugs?
PCSK9 inhibitors are a new class of drugs that lower LDL, or “bad,” cholesterol. Right now, there are two FDA-approved medications: alirocumab (Praluent) and evolocumab (Repatha). Studies show that PCSK9 inhibitors have a powerful effect and in some cases can actually prevent heart attacks or strokes.
Who qualifies for PCSK9 inhibitors?
On the basis of 1‐year LDL‐C levels, lipid‐lowering therapies, and clinical outcomes, the eligibility for the use of PCSK9 inhibitors at follow‐up was defined according to the following ESC/EAS criteria: (1) LDL‐C ≥3.6 mmol/L (140 mg/dL) at 1 year while on statin in combination with ezetimibe; or (2) LDL‐C ≥2.6 mmol/L …
What is the benefit of a PCSK9 inhibitor?
PCSK9 inhibitors are a type of medicine to lower cholesterol. They work by reducing your LDL cholesterol. Your provider might recommend a PCSK9 inhibitor if you have tried other treatments and your cholesterol is still high. You take PCSK9 inhibitors as an injection.
Is Inclisiran a PCSK9?
Inclisiran is a siRNA specific for PCSK9 that prevents translation of PCSK9 messenger RNA, leading to decreased concentrations of the protein and lower concentrations of LDL cholesterol.
Does insurance cover PCSK9?
Note: PCSK9 Inhibitors are typically covered under pharmacy benefit plans. Certain prescription drugs require an authorization for coverage to ensure that appropriate treatment regimens are followed.
How much does PCSK9 cost?
Starting in early March, the PCSK9 inhibitor will be available in the U.S. at a list price of $5,850 per year, 60% less than the original price of $14,625 annually. The reduction matches a price cut taken last year by rival Amgen on its competing drug Repatha.
Is Repatha the same as inclisiran?
The difference is that Repatha and Praluent bind with PCSK9 after it’s already been produced, while inclisiran blocks the expression of a gene that leads to the manufacturing of PCSK9. The technology behind inclisiran comes by way of Alnylam Pharmaceuticals, from which Medicines Co. licensed the drug in 2013.
Is Nexletol a PCSK9?
Notably, Nexletol and Nexlizet have the same indications as the PCSK9 inhibitors, namely, patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering with hypercholesterolemia.
How do you qualify for Repatha?
Eligibility Criteria: Subject to program limitations and terms and conditions, the Repatha® Copay Card is open to patients who have a Repatha® prescription and who have commercial or private insurance, including plans available through state and federal healthcare exchanges.
What are the side effects of PCSK9?
Side effects of PCSK9 inhibitors
- flu-like symptoms such as cold, nausea, back and joint pain.
- soreness or itchiness where you give the injection.
- muscle pain.
Is inclisiran covered by insurance?
As a healthcare provider-administered drug, inclisiran will be covered by the medical benefit pathway (as opposed to the pharmacy benefit pathway), which differs from other medications, including alirocumab and evolocumab.